Breast Cancer Clinical Trial
Official title:
Mindful-life: a Randomized Clinical Trial to Evaluate the Efficacy of a Mindfulness Based Intervention as Compared to Cognitive Behavioral Therapy for Depressive Symptoms and Quality of Life in Patients With Breast Cancer
Breast cancer is the most common cancer pathology among women worldwide and represents a
complex psychological challenge for those affected. Diagnosis and subsequent treatments can
have a significant impact not only on the physical well-being of people, but also on their
psychological well-being. Tumor-related distress is described as an "unpleasant emotional
multifactorial experience of a psychological, social and / or spiritual nature that can
interfere with the ability to effectively cope with cancer, physical symptoms and treatment"
from the National Comprehensive Cancer Network.Studies have shown that from one third to half
of breast cancer patients can experience psychological distress. The psychological distress,
understood as symptoms of anxiety, depression and stress, is related to a lower quality of
life, a lower compliance related to a lower efficacy of the treatments, a higher mortality
and a higher risk of suicide, so much so that this discomfort it is recognized as the sixth
vital sign in cancer treatment. Both the diagnosis of cancer and the treatments related to
the disease, can lead to the alternation of depressive phases and in some cases even to the
presence of major depression: it is estimated that the levels of depression reach thresholds
that oscillate between 5 and 25% between women suffering from breast cancer.
In reference to what are the interventions aimed at reducing depressive symptomatology in
patients with breast cancer, in this study we refer in particular to 2 treatments, of which
several studies attest to their effectiveness: interventions based on Mindfulness (MBI) and
interventions based on cognitive behavioral therapy (CBT).
Cognitive-behavioral therapy (CBT) is an empirically supported treatment for depression.
Numerous studies have shown that CBT is both effective in treating acute depression and
preventing subsequent relapses and relapses after the end of active treatment.
MBI-based interventions have been widely disseminated both at the clinical and research level
as short, cost-effective interventions.
Several systematic reviews have shown the effectiveness of MBIs in improving anxiety and
depressive symptoms, sleep, fatigue, disease adaptation and stress reduction, with coping and
well-being improved in patients with chronic illnesses including also the oncological
pathologies. In particular, a meta-analysis of studies conducted on women with breast cancer
confirmed the effectiveness of MBI in reducing symptoms of anxiety, depression and stress,
suggesting the importance of these treatments in improving the mental health of these women.
In addition, studies have shown that the improvements achieved are stable even at long-term
follow-up.
Status | Not yet recruiting |
Enrollment | 100 |
Est. completion date | December 31, 2022 |
Est. primary completion date | September 30, 2022 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - breast cancer; - understanding of the Italian language; - interruption of all psychotropic drugs at least one month before treatment and maintenance of interruption throughout the study or maintenance at baseline level; - legal capacity to express consent to the processing; - completion of all treatments except hormone therapy or trastuzumab at least 1 month before; - score> of 13 and <of 30 at the BDI (Beck Depression Inventory (BDI); - the ability to use at least e-mail management applications. Exclusion Criteria: - presence of serious psychological or psychiatric disorder, (eg severe major depressive disorder, psychotic disorder and bipolar disorder or abuse of active substances); - severe suicidal tendency; - presence of overt dementia; - previous participation in groups of Mindfulness Based Intervention and Cognitive Behavioral Therapy groups. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Turin, Italy |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | changes in depression symptoms | Beck Depression Inventory (BDI) | week 0, week 8, week 20, week 44 | |
Primary | changes in depression and anxiety symptoms | Depression Anxiety Stress Scale | week 0, week 8, week 20, week 44 | |
Primary | changes in HRV | Heart Rate Variability evaluation during practice | week 0, week 8, week 20, week 44 | |
Secondary | changes in brest cancer quality of life | Functional Assessment of Cancer Therapy - Breast (FACT-B) | week 0, week 8, week 20, week 44 | |
Secondary | changes in fatigue | Additional Concern Subscale of the Functional Assessment of Illness Therapy - Fatigue subscale (FACIT-F) | week 0, week 8, week 20, week 44 | |
Secondary | changes in self compassion | Self-Compassion Scale-forma breve (SCS-SF) | week 0, week 8, week 20, week 44 | |
Secondary | changes in sleep quality | Pittsburgh Sleep Quality Index (PSQI) | week 0, week 8, week 20, week 44 | |
Secondary | changes in attention and self awareness | Mindfulness Awareness Attention Scale (MAAS) | week 0, week 8, week 20, week 44 | |
Secondary | changes in trauma sypmtoms | Impact of Event Scale - Revised (IES-R) | week 0, week 8, week 20, week 44 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |